Chemical and biological properties of polymer-modified proteins.
Modification with polymers such as polyethylene glycol (PEG) can increase circulating lifetime, reduce immunogenicity and simplify the handling of pharmaceutical proteins. These benefits are currently exploited in six marketed polymer-modified protein therapeutics and about a dozen product candidates in clinical trials. However, traditional protein modification techniques are restricted by the limited control over polymer structure and the location and number of polymer attachment sites. New technology, in the form of chemical protein synthesis and the generation of precision polymers, has been applied to generate synthetic erythropoiesis protein (SEP). This promising treatment for anaemia has been synthesised with precision polymer modification methodology to improve the target protein pharmaceutical. The chemical and biological properties of proteins prepared by both traditional and novel approaches are contrasted in this discussion of chemical protein synthesis and polymer modification in protein drug discovery.
Kochendoerfer
Gerd
G
Gryphon Therapeutics, 600 Gateway Blvd., South San Francisco, CA 94080, USA. Gerd@gryphonRx.com
D000595:Amino Acid Sequence; D000740:Anemia / Q000628:therapy; D000818:Animals; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000378:metabolism; D015195:Drug Design; D006801:Humans; D007525:Isoelectric Focusing; D008956:Models, Chemical; D008969:Molecular Sequence Data; D011092:Polyethylene Glycols / Q000737:chemistry / Q000378:metabolism; D011108:Polymers / Q000737:chemistry*; D011506:Proteins / Q000737:chemistry*; D011994:Recombinant Proteins; D013997:Time Factors
D016207:Cytokines; D011108:Polymers; D011506:Proteins; D011994:Recombinant Proteins; C472014:synthetic erythropoiesis protein; D011092:Polyethylene Glycols